Here’s a wild thought: what if the same AI that’s mapping proteins and curing cancer could also tell you when to buy and sell stocks? Sounds like science fiction, right? Well, buckle up—because it’s happening, and the results are bonkers.
Let me set the scene. Demis Hassabis, the neuroscientist who founded DeepMind, just won the Nobel Prize for building AlphaFold2—an AI that mapped 200 million proteins in hours. Before this, figuring out protein shapes took researchers *years* in the lab. Now? Hours on a computer. That’s the kind of game-changing tech we’re talking about.
But here’s where it gets interesting for your portfolio.
A legendary quant investor named Louis Navellier has been using computers to pick stocks since the 1970s—back when most Wall Street guys thought he was absolutely nuts. Over 47 years, his system identified 676 stocks that doubled, including Microsoft in 1987, Apple and Nike in 1988, and Nvidia way before ChatGPT made it a household name. That Nvidia call alone? It would’ve turned $1,000 into over $1 million.
Not bad for a system built on a mainframe when slide rules were still cool.
But here’s the kicker: Navellier just added the same deep-learning AI that’s revolutionizing medicine to his stock-picking system. And the backtested results? They’re absolutely wild.
Take DXP Enterprises. Following his original system would’ve netted you a 615% gain. Add the AI timing layer? That becomes 3,626%. Same stock, same time period—just smarter timing. Or Broadcom: 292% becomes 6,284%. We’re talking 20x better returns across the board.
How does it work? The AI doesn’t replace the old system—it adds a new layer on top. Think of it like this: the original system is great at identifying *which* stocks to buy. The AI is obsessed with *when* to buy them. It uses pattern recognition to spot the exact moment a stock is about to pop, then tells you when to bail before it crashes.
The system uses a simple traffic light: green means buy, yellow means hold, red means sell. No complicated jargon. No pretending to understand what a “volatility-adjusted momentum oscillator” is.
Now, here’s the honest part: this is still backtested data. Past performance doesn’t guarantee future results, blah blah blah. But when you’re looking at a 47-year track record combined with the same AI that’s diagnosing cancer three years early, it’s hard to ignore.
The real question isn’t whether AI can improve stock picking—it’s how much better it can get. We’re living in a moment where the same technology rewriting medicine is now rewriting finance. That’s not hype. That’s just what’s happening.
If you’ve been sitting on the sidelines wondering whether AI is actually useful for anything beyond writing emails, here’s your answer: it might be about to make your portfolio a lot fatter.
